A carregar...
Bortezomib for the treatment of non-Hodgkin’s lymphoma
INTRODUCTION: Bortezomib, the first proteasome inhibitor (PI) to be evaluated in humans, is approved in the USA and Europe for the treatment of patients with multiple myeloma, and in the USA for patients with relapsed mantle cell lymphoma (MCL). AREAS COVERED: This review examines the role of bortez...
Na minha lista:
| Publicado no: | Expert Opin Pharmacother |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4856151/ https://ncbi.nlm.nih.gov/pubmed/25263936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2014.965142 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|